Torasemide extended release - Sarfez Pharmaceuticals
Alternative Names: SOAANZ; Torsemide extended release - Sarfez PharmaceuticalsLatest Information Update: 01 Apr 2024
Price :
$50 *
At a glance
- Originator Sarfez Pharmaceuticals
- Class Antihypertensives; Heart failure therapies; Small molecules; Sulfonamides
- Mechanism of Action Loop diuretics; Sodium-potassium-chloride symporter inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Oedema
Most Recent Events
- 31 Mar 2024 Sarfez Pharmaceuticals initiates a phase II trial for Oedema (overactive bladder in heart failure) in USA (PO) (NCT06206512)
- 11 Mar 2024 Sarfez Pharmaceuticals initiates a phase II trial for Oedema (renal sodium excretion in heart failure) in USA (PO) (NCT06176794)
- 13 Oct 2022 Launched for Oedema associated with heart failure and kidney disease in USA (PO)